Generated by AI
PolyPid Ltd. is a biopharmaceutical company focused on developing long-acting, locally administered therapeutics designed to deliver treatment precisely at the site of care. Its core platform, PLEX, is used to create controlled-release drug formulations that aim to improve therapeutic performance and address unmet medical needs across surgical care and other specialty areas. The company’s lead product candidate, D-PLEX100, is being developed for the prevention of surgical site infections, while its pipeline also includes oncology-focused programs such as OncoPLEX. PolyPid Ltd. works across clinical development, formulation design, and drug delivery technology, positioning itself in the broader market for targeted medicines and advanced pharmaceutical delivery systems. The company is headquartered in Petach Tikva, Israel.
Website18 Hasivim Street
Petah Tikva, 4959376
Israel
The latest articles about PYPD.
PolyPid Ltd (PYPD) heads into a November 28, 2026 PDUFA date with labeling talks underway, a $30 million Azurity partnership already paying off, and cash runway into 2028.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Jun 9's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about PYPD also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.